Literature DB >> 9821419

The clinical spectrum in a large kindred with autoimmune lymphoproliferative syndrome caused by a Fas mutation that impairs lymphocyte apoptosis.

A J Infante1, H A Britton, T DeNapoli, L A Middelton, M J Lenardo, C E Jackson, J Wang, T Fleisher, S E Straus, J M Puck.   

Abstract

Autoimmune lymphoproliferative syndrome (ALPS) is characterized by chronic, histologically benign splenomegaly and generalized lymphadenopathy, hypergammaglobulinemia, and autoantibody formation. ALPS has been attributed to defective programmed cell death of lymphocytes, most often arising as a result of mutations in the gene encoding the lymphocyte apoptosis receptor Fas/APO-l/CD95. We identified a novel mutation in the intracellular apoptosis signaling domain of Fas in 11 members of a family, individual members of which have been monitored for up to 25 years, with 1 or more features of ALPS. This study of a large number of family members carrying the same Fas defect demonstrates that ALPS is inherited in an autosomal dominant fashion but with a high degree of variability in clinical expression. Although 1 affected individual died of postsplenectomy sepsis and 1 has been treated for lymphoma, the Fas mutation in this family has been compatible with a healthy adulthood, as clinical features of ALPS have receded with increasing age.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9821419     DOI: 10.1016/s0022-3476(98)70102-7

Source DB:  PubMed          Journal:  J Pediatr        ISSN: 0022-3476            Impact factor:   4.406


  25 in total

1.  New take on comparative immunology: relevance to immunotherapy.

Authors:  Ena Wang; Adriana Albini; David F Stroncek; Francesco M Marincola
Journal:  Immunotherapy       Date:  2009-05       Impact factor: 4.196

Review 2.  Death receptors and caspases: role in lymphocyte proliferation, cell death, and autoimmunity.

Authors:  Sabine Adam-Klages; Dieter Adam; Ottmar Janssen; Dieter Kabelitz
Journal:  Immunol Res       Date:  2005       Impact factor: 2.829

Review 3.  How I treat autoimmune lymphoproliferative syndrome.

Authors:  V Koneti Rao; João Bosco Oliveira
Journal:  Blood       Date:  2011-09-01       Impact factor: 22.113

4.  Defective CD95/APO-1/Fas signal complex formation in the human autoimmune lymphoproliferative syndrome, type Ia.

Authors:  D A Martin; L Zheng; R M Siegel; B Huang; G H Fisher; J Wang; C E Jackson; J M Puck; J Dale; S E Straus; M E Peter; P H Krammer; S Fesik; M J Lenardo
Journal:  Proc Natl Acad Sci U S A       Date:  1999-04-13       Impact factor: 11.205

5.  Development of disseminated histiocytic sarcoma in a patient with autoimmune lymphoproliferative syndrome and associated Rosai-Dorfman disease.

Authors:  Girish Venkataraman; Kenneth L McClain; Stefania Pittaluga; V Koneti Rao; Elaine S Jaffe
Journal:  Am J Surg Pathol       Date:  2010-04       Impact factor: 6.394

6.  Autoimmune lymphoproliferative syndrome with defective Fas: genotype influences penetrance.

Authors:  C E Jackson; R E Fischer; A P Hsu; S M Anderson; Y Choi; J Wang; J K Dale; T A Fleisher; L A Middelton; M C Sneller; M J Lenardo; S E Straus; J M Puck
Journal:  Am J Hum Genet       Date:  1999-04       Impact factor: 11.025

Review 7.  The pre-ligand binding assembly domain: a potential target of inhibition of tumour necrosis factor receptor function.

Authors:  F K Chan
Journal:  Ann Rheum Dis       Date:  2000-11       Impact factor: 19.103

Review 8.  Incomplete penetrance in primary immunodeficiency: a skeleton in the closet.

Authors:  Conor Gruber; Dusan Bogunovic
Journal:  Hum Genet       Date:  2020-02-17       Impact factor: 4.132

9.  Autoimmune lymphoproliferative syndrome presenting with glomerulonephritis.

Authors:  Hirokazu Kanegane; Maria Marluce dos Santos Vilela; Yue Wang; Takeshi Futatani; Hiroyoshi Matsukura; Toshio Miyawaki
Journal:  Pediatr Nephrol       Date:  2003-04-04       Impact factor: 3.714

10.  The technological transformation of patient-driven human immunology research.

Authors:  Helen C Su
Journal:  Immunol Res       Date:  2009       Impact factor: 2.829

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.